NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
Clinical Trials
6 trialsNCT03795610 2025-07-25
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT03719326 2024-05-24
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
NCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT03980041 2022-11-25
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT02637531 2022-04-04
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Phase 1 Unknown